Brainstorm Cell Therapeutics Inc. (BCLI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chaim Lebovits | President & CEO | 649.59k | -- | 1971 |
| Dr. Ibrahim Dagher M.D. | Executive VP & Chief Medical Officer | 426.72k | -- | 1969 |
| Mr. Uri Yablonka | Executive VP, Chief Business Officer, Secretary & Director | 230.03k | -- | 1977 |
| Dr. Hartoun Hartounian Ph.D. | Executive VP & COO | -- | -- | 1960 |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor | -- | -- | -- |
| Ms. Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs | -- | -- | -- |
| Dr. Netta Blondheim-Shraga Ph.D. | Senior Vice President of Research and Development | -- | -- | -- |
Brainstorm Cell Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 27
Description
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 12, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC
Brainstorm Cell Therapeutics Inc. Earnings Date